TWI799871B - 三環并環類化合物，其製法與醫藥上的用途 - Google Patents
三環并環類化合物，其製法與醫藥上的用途 Download PDFInfo
- Publication number
- TWI799871B TWI799871B TW110118847A TW110118847A TWI799871B TW I799871 B TWI799871 B TW I799871B TW 110118847 A TW110118847 A TW 110118847A TW 110118847 A TW110118847 A TW 110118847A TW I799871 B TWI799871 B TW I799871B
- Authority
- TW
- Taiwan
- Prior art keywords
- preparation
- medical application
- tricyclic compound
- tricyclic
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010461834 | 2020-05-27 | ||
| CN202010461834.8 | 2020-05-27 | ||
| CN202010956281.3 | 2020-09-11 | ||
| CN202010956281 | 2020-09-11 | ||
| CN202011627054.2 | 2020-12-30 | ||
| CN202011627054 | 2020-12-30 | ||
| CN202110513435 | 2021-05-11 | ||
| CN202110513435.6 | 2021-05-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202204366A TW202204366A (zh) | 2022-02-01 |
| TWI799871B true TWI799871B (zh) | 2023-04-21 |
Family
ID=78745630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110118847A TWI799871B (zh) | 2020-05-27 | 2021-05-25 | 三環并環類化合物，其製法與醫藥上的用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230203060A1 (zh) |
| EP (1) | EP4159739A4 (zh) |
| CN (1) | CN115551867B (zh) |
| TW (1) | TWI799871B (zh) |
| WO (1) | WO2021239058A1 (zh) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| SG11202102377YA (en) | 2018-09-10 | 2021-04-29 | Mirati Therapeutics Inc | Combination therapies |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3849536A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3111977A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3890716A4 (en) | 2018-12-05 | 2022-12-21 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| JP7592601B2 (ja) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| PH12022550469A1 (en) | 2019-08-29 | 2023-02-27 | Array Biopharma Inc | Kras g12d inhibitors |
| EP4034123A4 (en) | 2019-09-24 | 2023-11-01 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| KR20220130126A (ko) | 2019-12-20 | 2022-09-26 | 미라티 테라퓨틱스, 인크. | Sos1 억제제 |
| KR20230137286A (ko) | 2020-09-11 | 2023-10-04 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제의 결정 형태 |
| WO2022066805A1 (en) | 2020-09-23 | 2022-03-31 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN114539286B (zh) * | 2020-11-24 | 2024-02-02 | 成都百裕制药股份有限公司 | 哌嗪衍生物及其在医药上的应用 |
| MX2023007084A (es) | 2020-12-15 | 2023-08-30 | Mirati Therapeutics Inc | Inhibidores de pan-kras de azaquinazolina. |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN114874234B (zh) * | 2021-02-05 | 2025-10-17 | 江苏先声药业有限公司 | 作为kras g12c抑制剂的三环类化合物及其应用 |
| CN118561952A (zh) | 2021-05-05 | 2024-08-30 | 锐新医药公司 | Ras抑制剂 |
| CR20230558A (es) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cáncer |
| WO2023008462A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| US20250282782A1 (en) | 2021-12-17 | 2025-09-11 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CR20250458A (es) | 2023-03-30 | 2025-11-21 | Revolution Medicines Inc | Composiciones para inducir la hidrólisis de ras gtp y sus usos |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| CN119285519B (zh) * | 2024-10-11 | 2025-04-18 | 无锡科华生物科技有限公司 | 一种5,5’-二甲基吡咯烷-3-醇的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110603258A (zh) * | 2017-05-11 | 2019-12-20 | 阿斯利康(瑞典)有限公司 | 抑制g12c突变型ras蛋白的杂芳基化合物 |
| TW202100532A (zh) * | 2019-03-05 | 2021-01-01 | 瑞典商阿斯特捷利康公司 | 稠合三環化合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008007661A1 (en) * | 2006-07-11 | 2008-01-17 | Takeda Pharmaceutical Company Limited | Tricyclic heterocyclic compound and use thereof |
| TW201938561A (zh) * | 2017-12-08 | 2019-10-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| HUE060684T2 (hu) * | 2019-12-11 | 2023-04-28 | Lilly Co Eli | KRas G12C inhibitorok |
-
2021
- 2021-05-25 TW TW110118847A patent/TWI799871B/zh not_active IP Right Cessation
- 2021-05-27 CN CN202180032505.4A patent/CN115551867B/zh active Active
- 2021-05-27 EP EP21813120.9A patent/EP4159739A4/en not_active Withdrawn
- 2021-05-27 US US17/927,961 patent/US20230203060A1/en active Pending
- 2021-05-27 WO PCT/CN2021/096424 patent/WO2021239058A1/zh not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110603258A (zh) * | 2017-05-11 | 2019-12-20 | 阿斯利康(瑞典)有限公司 | 抑制g12c突变型ras蛋白的杂芳基化合物 |
| TW202100532A (zh) * | 2019-03-05 | 2021-01-01 | 瑞典商阿斯特捷利康公司 | 稠合三環化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115551867A (zh) | 2022-12-30 |
| EP4159739A1 (en) | 2023-04-05 |
| CN115551867B (zh) | 2024-02-20 |
| US20230203060A1 (en) | 2023-06-29 |
| EP4159739A4 (en) | 2024-07-10 |
| WO2021239058A1 (zh) | 2021-12-02 |
| TW202204366A (zh) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI799871B (zh) | 三環并環類化合物，其製法與醫藥上的用途 | |
| IL290276A (en) | Tetracyclic compound, preparation method and use thereof | |
| EP4397664A4 (en) | CYCLIC COMPOUND FUSED TO A PYRIMIDINE, PROCESS FOR ITS PREPARATION AND ITS USE | |
| EP3896062A4 (en) | ISOINDOLINE COMPOUND, METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE OF ISOINDOLINE COMPOUND | |
| SG11202105850YA (en) | Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof | |
| EP3636646A4 (en) | HETEROARYL PYRAZOL DERIVATIVE AND MANUFACTURING METHOD FOR IT AND MEDICAL USES THEREOF | |
| DK3312177T3 (da) | Tricyklisk derivatforbindelse, fremgangsmåde til at fremstille samme og farmaceutisk sammensætning omfattende samme | |
| ES2981449R1 (es) | Fosfato férrico, método de preparación y aplicación del mismo | |
| DK3381469T3 (da) | Anti-erbb2 antistoflægemiddelskonjugat og sammensætning deraf, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| EP3967687A4 (en) | SUBSTITUTED PHENYLPROPENYLPYRIDE DERIVATIVE AND METHOD OF MANUFACTURE THEREOF AND MEDICAL USE THEREOF | |
| EP3412669A4 (en) | TRICYCLIC COMPOUND FOR PROTEIN INHIBITOR CONTAINING BROMODOMAINE AND PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| PL3586071T3 (pl) | Szyba zespolona, sposób jej wytwarzania i jej zastosowanie | |
| DK3404024T3 (da) | Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser | |
| EP3801727A4 (en) | High torque catheter and methods of manufacture | |
| IL286993A (en) | Voruciclib poly morphs and methods of making and using thereof | |
| EP3760191A4 (en) | PHARMACEUTICAL COMPOSITION, PROCESS FOR PREPARATION AND USE OF THE LATTER | |
| EP3406602A4 (en) | 1-sulfonamido-4-aryloxy compound, and preparation method and medicinal application thereof | |
| EP3646855C0 (en) | COMPOSITION FOR SOLID PREPARATION FOR ORAL USE COMPRISING A PROTON PUMP INHIBITOR, SOLID PREPARATION FOR ORAL USE COMPRISING SAME, AND METHOD FOR PREPARING SAME | |
| EP3560921A4 (en) | QUINAZOLINE COMPOUND AND PROCESS FOR THE PREPARATION, USE AND CORRESPONDING PHARMACEUTICAL COMPOSITION | |
| IL289375A (en) | Pyrazolopyrimidine compound, preparation method for same, and applications thereof | |
| EP3805212A4 (en) | 3-OXAZOLINONE COMPOUND, METHOD FOR PREPARING THEREOF, AND PHARMACEUTICAL USE THEREOF | |
| EP4112607A4 (en) | AMINOLIPID COMPOUND, ITS PREPARATION METHOD AND ITS APPLICATION | |
| IL282817A (en) | New material, production method, and its use | |
| IL304719A (en) | Methods of preparation of secretomes, and uses thereof | |
| ZA202209741B (en) | Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |